Kurt Kroenke, MD, LTC, MC; Deborah M. Omori, MD, MAJ, MC; John O. Simmons, MD, MAJ, MC; David R. Wood, DO; Nancy J. Meier, RN
Phenylpropanolamine is a popular decongestant and appetite suppressant, with an estimated 5 billion doses consumed annually (1). However, label directions still caution people with hypertension against using products containing phenylpropanolamine. Isolated reports of complications have often involved either phenylpropanolamine overdoses or a more potent isomeric form unavailable in the United States (1-3). Given the prevalence of hypertension and the wide availability of phenylpropanolamine, the rare occurrence of hypertensive events in persons taking phenylpropanolamine is just as likely coincidental as causative. The purported risks of phenylpropanolamine remain debatable (4, 5). Numerous clinical trials have shown the safety of phenylpropanolamine in normotensive
Kroenke K, Omori DM, Simmons JO, Wood DR, Meier NJ. The Safety of Phenylpropanolamine in Patients with Stable Hypertension. Ann Intern Med. ;111:1043–1044. doi: 10.7326/0003-4819-111-12-1043
Download citation file:
© 2019
Published: Ann Intern Med. 1989;111(12):1043-1044.
DOI: 10.7326/0003-4819-111-12-1043
Cardiology, Coronary Risk Factors, Hypertension, Nephrology, Prevention/Screening.
Results provided by: